Suppression of RAC1-driven malignant melanoma by Group A PAK inhibitors

Activating mutations in the RAC1 gene have recently been discovered as driver events in malignant melanoma. Expression of this gene is associated with melanocyte proliferation, and melanoma cells bearing this mutation are insensitive to BRAF inhibitors such as vemurafenib and dabrafenib, and also ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Araiza-Olivera, Daniela, Feng, Yayi, Semenova, Galina, Prudnikova, Tatiana Y., Rhodes, Jennifer, Chernoff, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814328/
https://www.ncbi.nlm.nih.gov/pubmed/29059171
http://dx.doi.org/10.1038/onc.2017.400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814328/
https://www.ncbi.nlm.nih.gov/pubmed/29059171
http://dx.doi.org/10.1038/onc.2017.400

Ejemplares similares